Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Did You Know Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationSGLT2Issue 731

Empagliflozin (an SGLT2 inhibitor) Approved by European Commission

The European Commission has approved empagliflozin 10 mg and 25 mg once-daily tablets for use in adults when glycemic control is not achieved from diet and exercise. The European Commission endorsed empagliflozin for approval in March after the U.S. FDA delayed the approval and requested more data. A new drug application has been accepted by the FDA for a combination of empagliflozin and linagliptin, though, and will be reviewed. This approval is based on more than 10 international trials looking at more than 13,000 adults with type 2 diabetes. The phase 3 studies produced significantly reduced HbA1c, body weight and blood pressure when used as monotherapy and in combination with preexisting treatments. Lilly News Release, Mau 2014 

Advertisement
Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2014 and appeared in  MedicationSGLT2Issue 731

Past five issues: Issue 778 | Diabetes Clinical Mastery Series Issue 237 | GLP-1 Special Editions April 2015 | Issue 777 | Diabetes Clinical Mastery Series Issue 236 |

2015 Most Popular Articles:

A Potential New Type 2 Diabetes Indicator
Posted April 02, 2015
Glyburide Used for Gestational Diabetes May Increase Risk of Birth Complications
Posted April 02, 2015
A Third Treatment Option in Uncontrolled Type 2 Diabetes
Posted April 02, 2015
Gastric Electrical Stimulation an Alternative to Insulin Injections?
Posted April 02, 2015
A Novel Scale May Indicate Glycemic Progression to Type 1 Diabetes
Posted April 02, 2015
Women Retain Insulin Sensitivity Better than Men
Posted April 02, 2015
Artificial Pancreas Software Algorithm Receives Approval in Europe
Posted April 02, 2015
Glycemic Control and Medications in T2DM Elderly with Dementia
Posted April 02, 2015
HbA1c and OGTT Performance in Prediabetic Obese Adolescents
Posted April 02, 2015
Type 2 Diabetes and Other Diseases Risk Related to Increase in Artificial Light?
Posted April 02, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percent of your patients have reached their A1c target?
CME/CE of the Week
Vickie Driver, DPM, MS, FACFAS

Category: Wound Care
Credits: 1.0



Search Articles On Diabetes In Control